Abstract
BackgroundDysregulation of microRNAs (miRNAs) has been reported to be involved in the neuroinflammatory pathogenesis of PD. This study aimed to investigate the serum expression of microRNA‐150 (miR‐150) in Parkinson's disease (PD) patients and further uncover the regulatory effect of miR‐150 on neuroinflammation.MethodsQuantitative Real‐Time PCR was used to measure the expression of miR‐150. A receiver operating characteristic curve was applied to evaluate the diagnostic value of miR‐150. The effect of miR‐150 on neuroinflammation was analyzed by examining its correlation with proinflammatory cytokines and gain‐of‐function experiments in microglia treated with LPS.ResultsSerum miR‐150 expression was downregulated in PD patients compared with the healthy controls, and served as a candidate diagnostic biomarker for the screening of PD cases. Negative correlation was found between miR‐150 levels and the levels of procytokines in PD patients. By the treatment of LPS, microglia BV2 cells had a reduced expression of miR‐150, and the enhanced neuroinflammatory responses were inhibited by the overexpression of miR‐150. AKT3 was verified as a target of miR‐150 in BV2 cells.ConclusionAll the data of this study revealed that the decreased serum miR‐150 serves as a potential diagnostic biomarker. The methods to increase miR‐150 expression may have a beneficial effect in PD via suppressing the neuroinflammation by targeting AKT3.
Highlights
Parkinson's disease (PD) is a frequent neurodegenerative disease with the incidence rate of 2% among the population over 65 years old (Ascherio & Schwarzschild, 2016)
This study was carried out to identify a novel biomarker for the diagnosis of PD and explore the regulatory effect of miR-150 on neuroinflammation in the pathogenesis of PD
Through the in vitro experiments, this study found that the overexpression of miR-150 in LPS-treated BV2 cells led to the inhibited release of IL-1β, IL-6, and TNFα
Summary
Parkinson's disease (PD) is a frequent neurodegenerative disease with the incidence rate of 2% among the population over 65 years old (Ascherio & Schwarzschild, 2016). Great efforts have been carried out for the treatment of PD, but the strategies that could significantly improve PD clinical features remain limited (Kalia, Kalia, & Lang, 2015). Aberrant expression of miRNAs in disease progression and its stability in body fluid, especially in serum, leading to miRNAs becomes a class of biomarkers for the diagnosis of various diseases (Piscopo et al, 2018; Qiu, Li, Wang, & Sun, 2017). In addition to the clinical significance, the therapeutic potentials of miRNAs have been highlighted through regulating neuroinflammation in PD progression (Cao, Wang, Qu, Kang, & Yang, 2018). To explore novel molecule that has diagnostic and therapeutic potential in PD progression, this study aimed to investigate the serum expression of miR-150 in patients with PD and further explore the relationship of miR-150 with neuroinflammation in patients and microglia
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
